Inês Marques, Ramon Andrade de Mello, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal.
World J Gastroenterol. 2013 Nov 28;19(44):7955-71. doi: 10.3748/wjg.v19.i44.7955.
Colorectal cancer (CRC) is the fourth most commonly diagnosed cancer and the second leading cause of cancer death in both men and women in the United States, with about 142820 new cases and 50830 deaths expected in 2013. Metastatic disease (mCRC) remains a challenge for oncologists worldwide due to its potential comorbidities. Recently, chemotherapy regimens containing 5-fluorouracil, leucovorin, oxaliplatin and irinotecan combinations are a standard of care in the metastatic disease. Currently, biological therapies involving vascular endothelial growth factor and epidermal growth factor receptor pathways, such as bevacizumab and cetuximab, have emerged as good option for improving mCRC patient survival. Now, aflibercept plus standard chemotherapy has also been approved in second line regimen for mCRC patients. Our review will discuss novel biological drugs and their indications for mCRC patients and will bring future perspectives in this regard.
在美国，结直肠癌（CRC）是男性和女性中第四大常见癌症，也是癌症死亡的第二大主要原因，预计 2013 年将有 142820 例新发病例和 50830 例死亡。转移性疾病（mCRC）仍然是全世界肿瘤学家面临的挑战，因为它可能伴有合并症。最近，含有 5-氟尿嘧啶、亚叶酸钙、奥沙利铂和伊立替康联合化疗方案是转移性疾病的标准治疗方法。目前，涉及血管内皮生长因子和表皮生长因子受体途径的生物疗法，如贝伐单抗和西妥昔单抗，已成为改善 mCRC 患者生存的一种选择。现在，阿柏西普联合标准化疗也已被批准用于 mCRC 患者的二线治疗方案。我们的综述将讨论新型生物药物及其在 mCRC 患者中的适应证，并将对此进行未来展望。
